The stark figures, published on Thursday, and believed to be the first to quantify the potential impact of antimicrobial resistance (AMR) – drug-resistant infections or superbugs – will be used to make the case to global leaders that urgent action is needed. To put the figures in context there are currently 8.2 million deaths a year from cancer and annual global GDP stands at $70tn to $75tn, with the UK figure around $3tn.
11 December 2014 | The Guardian
TB treatment must be shorter, simpler, less toxic, and more tolerable and affordable. Activists can contribute to the development and uptake of improved TB treatment by calling attention to research, quality of medications, and access priorities.
04 June 2014 | TAG
More than 17% of antiretroviral-naive men who have sex with men (MSM) in a large US study carried antiretroviral-resistant virus, according to a nationwide analysis by the Centers for Disease Control and Prevention (CDC)]. MSM under 30 years old had close to a 19% prevalence of transmitted resistant HIV.
06 March 2014 | NATAP
As is plainly obvious to anyone doing HIV care, the incidence of new patients with the sort of HIV drug resistance for which the test was developed has plummeted. There simply aren't many new patients out there who have multiple mutations, especially in the PI-drug class, and who will need the computational black-box firepower provided by a vircoTYPE.
27 November 2013 | The BodyPRO
An exclusive worldwide licensing agreement has been signed for the rights to a series of diagnostic tests to determine drug resistance and co-receptor tropism in human immunodeficiency virus (HIV). The tests will be used by physicians and researchers to monitor the success of anti-HIV treatment by determining drug resistance and the ability of the virus to infect different cells within the patient. The HIV assays also can be used by academic and corporate researchers to develop novel strategies to block HIV replication.
03 July 2013 | University Hospitals Case Medical Center
Wide HIV testing and early treatment woul lower HIV transmission, AIDS and death rates, but double the rate of multidrug resistance (MDR) to antiretrovirals.
26 March 2013 | AIDSMeds
Results of a new study demonstrate that computer models can predict how HIV patients whose drug therapy is failing will respond to a new treatment. Crucially for patients in poorer countries, the models do not require the results of expensive drug resistance tests to make their predictions. The study also showed that the models were able to identify alternative drug combinations that were predicted to work in cases where the treatment used in the clinic had failed, suggesting that their use could avoid treatment failure.
14 March 2013 | Eurekalert Inf Dis
Just over 16% of US residents newly diagnosed with HIV infection in 10 metropolitan areas or states carried antiretroviral-resistant virus, according to a CDC study spanning the years 2007 to 2010.
11 March 2013 | NATAP
The rate of drug-resistant HIV transmission in the U.S. appears to be holding steady, according to the most recent CDC figures.
07 March 2013 | MedPage Today HIV/AIDS
Among the key changes are additional information about the most recently approved antiretroviral agents and a recommendation that newly infected people with HIV should be offered combination ART. The guidelines continue to recommend treatment for all people with HIV, both to reduce the risk of disease progressionand for the prevention of HIV transmission.
15 February 2013 | HIVandHepatitis.com